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The main goal of the management of vesicoureteral reﬂux (VUR) is prevention of recurrent urinary tract infections (UTIs),
and thereby prevention of renal parenchymal damage possibly ensuing from these infections. Long-term antibiotic prophylaxis is
commonpracticeinthemanagementofchildrenwithVUR,asrecommendedin1997intheguidelinesoftheAmericanUrological
Association. We performed a systematic review to ascertain whether antibiotics can be safely discontinued in children with VUR
and whether prophylaxis is eﬀective in the prevention of recurrent UTIs and renal damage in these patients. Several uncontrolled
studies indicate that antibiotic prophylaxis can be discontinued in a subset of patients, that is, school-aged children with low-
grade VUR, normal voiding patterns, kidneys without hydronephrosis or scars, and normal anatomy of the urogenital system.
Furthermore, a few recent randomized controlled trials suggest that antibiotic prophylaxis oﬀers no advantage over intermittent
antibiotic therapy of UTIs in terms of prevention of recurrent UTIs or new renal damage.
Copyright © 2008 Michiel Costers et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Vesicoureteral reﬂux (VUR) is deﬁned as the abnormal,
retrograde ﬂow of urine from the urinary bladder into
the upper urinary tract. VUR can be primary, caused
by an anatomically insuﬃcient vesicoureteric junction, or
secondary, due to an infravesical obstruction. VUR aﬀects 1–
3% of otherwise healthy children. However, the prevalence
rises to 10–20% in children with antenatally detected
hydronephrosis, to 30% in siblings of children with known
VUR, and to 30–40% in children with a proved urinary tract
infection (UTI) [1, 2].
The retrograde ﬂow of urine from the bladder into
the ureter may transport bacteria to the upper urinary
tract, possibly predisposing these children to febrile UTI,
which can result in permanent renal parenchymal damage.
Ultimately,renaldamageresultsinreﬂuxnephropathywhich
could cause hypertension and decreased renal function
although the risk seems to be lower than previously thought
[3–5].
The clinical presentation of patients with VUR is diverse
and dependent on age and gender [6]. Typically, VUR is
detected during the evaluation of a child, usually a girl,
presentingwithUTI[7].Sincethewidespreaduseofprenatal
ultrasonography, hydronephrosis is often detected in utero,
possibly leading to the diagnosis of VUR in the perinatal
period [8]. Neonatal VUR is more common in boys and
often associated with congenital renal dysplasia. A history of
familial VUR and investigation of an overactive bladder can
also lead to the diagnosis of VUR [9, 10].
In 1999, the practice guideline from the American
Academy of Pediatrics recommended a renal ultrasound
and either a classic radiographic voiding cystourethrography
or a direct radionuclide cystography after a ﬁrst UTI in
children aged 2–24 months [11]. However, the recently
revised guideline of the National Institute for Health and
Clinical Excellence (NICE) constitutes a major departure
from this diagnostic strategy [12, 13]. For infants and
children without recurrent or atypical UTI, no imaging tests
are recommended when they are 6 months or older, and an2 Advances in Urology
ultrasound within 6 weeks of the ﬁrst UTI will suﬃce when
they are younger than 6 months.
Spontaneous resolution of VUR due to the natural elon-
gation of the vesicoureteral junction is possible, especially in
patients with the lower grades of VUR or unilateral reﬂux
and in boys; grades I–III reﬂux resolves at a rate of 13% each
year during the ﬁrst 5 years of follow-up and at 3.5% yearly
thereafter, and grade IV reﬂux resolves at a yearly rate of 5%
[14].
The main goal of the management of VUR should be
prevention of recurrent febrile UTI, and thereby prevention
of the ensuing renal parenchymal damage [6]. The treat-
ment options include intermittent therapy of episodes of
UTI, medical therapy with long-term antibiotic prophylaxis,
endoscopic therapy, or surgical therapy.
The desire to update our therapeutic algorithm for chil-
dren with VUR stimulated us to conduct a systematic review
of the role of antibiotic prophylaxis in the management
of these children. More speciﬁcally, we wanted to ascertain
whether antibiotics can be safely discontinued and whether
prophylaxis is eﬀective in the prevention of recurrent UTIs
and renal damage in these patients.
2. METHODS
Medline (1966 to June 2008), Embase (1988 to June 2008),
and Cochrane Central Register of Controlled Trials were
searched using the combined search terms “vesicoureteral
reﬂux” (MeSH) and “antibiotic prophylaxis” (MeSH).
National Guideline Clearinghouse, NICE Guidance, and
Cochrane Database of Systematic Reviews were searched
using the search terms “vesicoureteral reﬂux” and “urinary
tractinfectioninchildren.”Referencelistsofarticles,reviews,
and studies were searched for additional studies.
After the search was performed, the titles of all retrieved
publications were screened. If the title indicating the paper
was potentially relevant, the abstract was reviewed. The full
paper was reviewed if the abstract suggested that the paper
was indeed relevant. This process was performed by one
reviewer (MC Michiel Costers) and thereafter validated by
two other reviewers (GB Guy Bogaert and RVDL Rita Van
Damme-Lombaerts).
Five uncontrolled studies evaluated the eﬀect of stopping
antibiotic prophylaxis in this patient group [15–19].
Five randomized controlled trials (RCTs) and one cohort
study that compared antibiotic prophylaxis with no treat-
ment (i.e., surveillance with intermittent therapy of episodes
of UTI) for children with VUR were included in this review
[20–25].
Two Cochrane systematic reviews and two guidelines on
the topic of antibiotic prophylaxis for children with VUR
were identiﬁed [12, 26–28] .I n s t e a do fp e r f o r m i n gam e t a -
analysis on this limited number of RCTs, we present the
results of these studies.
3. RESULTS AND DISCUSSION
Long-term antibiotic prophylaxis remains a common prac-
tice in the management of children with VUR. The most
commonly used drugs are nitrofurantoin, cotrimoxazole,
amoxicillin, and cephalosporins [29, 30]. However, these
medications may cause side eﬀects and promote the devel-
opment of resistant bacteria [22, 23, 25, 31]. Furthermore,
the optimal duration of prophylaxis and optimal (low) dose
of antibiotic are unclear, and compliance with this long-term
treatment is not always assured.
In the 1960’s, animal data showed that a UTI in the
presence of VUR can cause renal damage. It was then
hypothesized that sterilization of the urine could prevent
pyelonephritis, and thereby also the resulting parenchymal
damage.
At the end of the 1970’s, two very small studies
indeed suggested that prophylactic antibiotics may prevent
recurrent UTIs in children, particularly during the period
of prophylaxis. Smellie et al. [32] compared 6–12 months
of antibiotic prophylaxis (cotrimoxazole or nitrofurantoin)
versus no treatment in 53 children with acute UTI. None
of the children in the intervention group had a UTI during
the prophylaxis period, while 11 children in the control
group presented with a UTI. Twelve months after stopping
prophylacticantibiotics,8children(32%)intheintervention
group compared with 13 (64%) in the control group had
suﬀered from a recurrent UTI.
Lohr et al. [33] performed a crossover study on 18
girls with a history of at least 3 episodes of bacteriuria in
the previous year (including 1 girl with VUR). Each child
was placed on nitrofurantoin for 6 months and on placebo
for a similar period. There were 35 episodes of bacteriuria
(4.2 episodes/patient/year) in the patients taking the placebo
versus 2 episodes (0.2 episodes/patient/year) in the children
taking the antibiotic. Fourteen symptomatic UTIs (1.7
episodes/patient/year) occurred during the placebo periods,
and none during the prophylaxis periods.
In 1997, the Pediatric Vesicoureteral Reﬂux Guidelines
Panel of the American Urological Association (AUA) recom-
mended continuous antibiotic prophylaxis as initial therapy
for children with reﬂux grades I–IV [28]. However, this
recommendation was based on expert opinion rather than
on clear scientiﬁc evidence.
3.1. Discontinuationofantibioticprophylaxis
During the following decades, this therapeutic practice has
been challenged on multiple occasions. First, several authors
demonstrated that in certain circumstances antibiotic pro-
phylaxis can be safely discontinued.
Cooper et al. [15] discontinued antibiotic prophylaxis
in 51 children with persistent primary VUR (grades I–IV).
All children were old enough to describe the symptoms of
UTI (mean age at stop of antibiotics = 8.6 years), and had a
minimal orquestionablehistoryoftrueUTI,normalvoiding
patterns, and kidneys with no signiﬁcant hydronephrosis
or scars. A retrospective chart review revealed 6 episodes
(11.8%) of UTI after cessation of prophylaxis (mean follow-
up oﬀ antibiotics = 3 . 7y e a r s ) :1c a s eo fc y s t i t i sa n d5c a s e so f
clinically presumptive pyelonephritis. None of the children
showed new renal scars on renal ultrasound. However, it
should be noted that renal ultrasound has low sensitivity for
detection of renal scars.Michiel Costers et al. 3
TheretrospectivechartreviewbyThompsonetal.[16]of
196 children (mean age at stop of antibiotics = 6y e a r s )w h o
had been withdrawn from prophylactic antibiotics (mean
follow-up oﬀ antibiotics = 3.4 years) despite persistent reﬂux
(all grades) showed a similar rate of UTIs per patient/year on
or oﬀ antibiotics (0.29 on versus 0.24 oﬀ). Paradoxically, for
the 39 children with high-grade reﬂux IV or V, there was a
diﬀerence in the rate of UTIs per patient/year seemingly in
favor of discontinuation of antibiotic prophylaxis (0.39 on
versus 0.18 oﬀ). In addition, the rate of new renal scarring
on DMSA scan after stop of antibiotics was comparable with
the rate during prophylaxis (2.6% on versus 3.6% oﬀ).
Hellerstein and Nickell [17] followed (mean follow-up
of 3.7 years) 66 children (mean age at stop of antibiotics =
4.4 years for the girls and 3.1 years for the boys) considered
at risk for UTI (including 48 children with VUR) after
completion of the initial course of prophylactic antibiotics.
During the initial course of prophylactic antibiotics, 16
children presented with UTIs, with voiding dysfunction
and abnormal kidney(s) being identiﬁed as risk factors for
these infections. Twenty-eight children had UTI during the
follow-up period, but 13 of these children were receiving an
antibiotic at the time of the infection. Voiding dysfunction
was again identiﬁed as a risk factor for infection in this time
period.
Al-Sayyad et al. [18] also performed a retrospective chart
review of 78 children of 4 years or older with persistent
VUR (mean age at stop of antibiotics = 5.7 years) and
with reﬂux grade less than IV and normal voiding pattern
or mild voiding dysfunction, who were taken oﬀ antibiotic
prophylaxis (mean follow-up oﬀ antibiotics = 37.7 months).
UTI developed in 9 children (11.5%): 8 cases of cystitis
and 1 case of clinically presumptive pyelonephritis. None
of the children had new renal scarring detected on renal
ultrasound.
Fifty-four children (mean age at stop of antibiotics = 6
years) with persistent VUR (all grades, but only 2 patients
had high-grade reﬂux IV or V at the stop of antibiotics) were
followed prospectively after discontinuation of antibiotic
prophylaxis (mean follow-up oﬀ antibiotics = 4.4 years) in
the study by Georgaki-Angelaki et al. [19]. All these children
were old enough to describe symptoms of UTI, and had
normal voiding patterns, kidneys without hydronephrosis
or new scar lesions, and a period of at least 2 years
without UTI. The number of symptomatic UTI episodes
was similar during the on- and oﬀ-prophylaxis periods: 9
(cystitis3andpyelonephritis6)and8episodes(cystitis1and
pyelonephritis7),respectively.Nonewscarsweredetectedby
DMSA scan at the end of the prophylaxis period (50 children
tested) and at the end of the follow-up period (33 children
tested). In none of the children, renal function deteriorated.
3.2. Antibioticprophylaxisversusintermittenttherapy
ofepisodesofurinarytractinfection
The small studies by Reddy et al. [20] and Craig et al. [21]
were the ﬁrst to compare antibiotic prophylaxis with no
treatment. In the study by Reddy et al. [20], 43 children with
VUR were randomly assigned to one of three groups: daily
urine nitrate tests without antibiotic prophylaxis (surveil-
lance), daily urine nitrate tests with antibiotic prophylaxis 3
times a week (intermittent prophylaxis), or daily antibiotic
prophylaxis (continuous prophylaxis). The incidence of UTI
in the 3 groups was as follows: 1/13, 2/14, and 5/16 in
the continuous prophylaxis, intermittent prophylaxis, and
surveillance groups, respectively.
In the study by Craig et al. [21], 41 children under 3
months of age with asymptomatic VUR received antibiotic
p r o p h y l a x i s( c o t r i m o x a z o l ef o r3y e a r s )o rp l a c e b o .T w o
children in the placebo group (n = 20) and no child in the
antibiotic group (n = 21) developed UTI, and none of the
children developed new renal damage on DMSA scan.
The multicenter study of Garin et al. [22] evaluated the
role of VUR in causing UTI and renal parenchymal damage
in 218 patients after an episode of acute pyelonephritis, and
determined whether antibiotic prophylaxis (nitrofurantoin
or cotrimoxazole for 1 year) could prevent UTI and renal
parenchymal damage in the subgroup of patients with mild
or moderate VUR (grades I–III). After 1 year of follow-
up, the presence of VUR did not signiﬁcantly increase the
incidence of UTI or renal scarring on DMSA scan. Among
the 113 patients with VUR, antibiotic prophylaxis did not
resultinaclinicaladvantagetopreventUTI(23.6%onversus
22.4% oﬀ prophylaxis) or renal scars (9% on versus 3.4% oﬀ
prophylaxis). Ironically, recurrent acute pyelonephritis was
more frequent in the intervention group than in the control
group (12.9% on versus 1.7% oﬀ prophylaxis) and in all
7 cases, while on antibiotics the oﬀending bacteria showed
resistance to the used antibiotic.
In the updated meta-analysis for the Cochrane Database
of Systematic Reviews [26], the authors stated that the
studies by Reddy et al. [20] and Garin et al. [22]w e r e
unable to demonstrate a diﬀerence in the risk for UTI
or renal parenchymal damage between intervention and
control groups, and also that diﬀerences cannot be excluded
because of the small number of patients studied so far.
Furthermore,theyconcludedthatcombinedtherapy(antibi-
otic prophylaxis plus surgery) oﬀers no advantages over
antibiotic prophylaxis alone in terms of risk for UTI or renal
parenchymal damage.
Conway et al. [23] studied a cohort of 611 children aged
6 years or younger with a ﬁrst episode of UTI and without
signiﬁcant comorbidity to identify risk factors for recurrent
UTI and examine the eﬀect of antibiotic prophylaxis on
r e c u r r e n tU T I .A g eo f3 – 5y e a r sa n dh i g hg r a d eo fr e ﬂ u x( I V
or V) were identiﬁed as risk factors for recurrent UTI; the
impact of voiding pattern was not evaluated in this study.
They found that antibiotic prophylaxis had no signiﬁcant
eﬀect on the risk of recurrence of UTI (hazard ratio of 1.01),
even when stratiﬁed by type of antibiotic and stratiﬁed for
covariates such as sex, race, age, and result of VCUG. Among
the 83 children with recurrent UTI, a nested case-control
study was performed to determine risk factors for isolation
of resistant bacteria. Antibiotic prophylaxis clearly increased
the likelihood of the infection being caused by a resistant
pathogen (odds ratio of 7.50).
A French multicenter study by Roussey-Kesler et al. [24]
evaluated whether antibiotic prophylaxis (cotrimoxazole for4 Advances in Urology
18 months) could reduce the recurrence of UTI in 225 young
children with grade I, II, or III VUR. Eighteen months later,
recurrence of all UTIs and febrile UTIs was not signiﬁcantly
diﬀerent between the intervention and control groups: 17%
versus 26% (P = .15) and 13% versus 16% (P = .52),
respectively. When patients with grades I–III reﬂux were
analyzed separately, again no signiﬁcant diﬀerences were
observed (P = .22, P = .23, and P = .57, resp.). However,
prophylaxis signiﬁcantly reduced UTI in boys (P = .013) but
not in girls (P = .8), and then only in those boys with grade
III VUR (P = .04).
Finally, an Italian multicenter study by Pennesi et al.
[25] assessed the eﬀectiveness of antibiotic prophylaxis
(cotrimoxazole for 2 years) in preventing pyelonephritis and
in avoiding the occurrence of new scars in 100 children with
gradeII,III,orIVVURatﬁrstepisodeofpyelonephritis,who
were younger than 30 months. After 2 years of follow-up, 18
children (36%) in the intervention group and 15 children
(30%) in the control group had at least 1 pyelonephritis
recurrence. Thus, the risk for having at least 1 pyelonephritis
recurrence was even slightly higher in the intervention group
than in the control group (relative risk of 1.2). While all
episodes of pyelonephritis in the control group were caused
by sensitive strains of Escherichia coli, multiresistant bacteria
(all resistant to cotrimoxazole among other antibiotics) were
responsible for all infections in the intervention group.
Furthermore, the presence of renal scars on DMSA scan was
the same in children with or without antibiotic prophylaxis
(relative risk of 1.2).
According to the recently revised NICE guideline, antibi-
otic prophylaxis is not routinely recommended in children
after ﬁrst-time UTI, and should only be considered after
recurrent UTI [12, 13].
4. CONCLUSION
Despite the lack of evidence for its eﬀectiveness, long-term
antibiotic prophylaxis has been a common practice in the
management of children with VUR for decades. However,
several uncontrolled studies (total of 379 children) indicate
that antibiotic prophylaxis can safely be discontinued in
a subset of patients, that is, school-aged children with
low-grade VUR, normal voiding patterns, kidneys without
hydronephrosis or scars, and normal anatomy of the urogen-
ital system.
More importantly, several recent RCTs suggest that
antibiotic prophylaxis (with cotrimoxazole) oﬀers no advan-
tage over intermittent antibiotic therapy of UTIs in terms
of prevention of recurrent UTIs or new renal damage.
However, further research is still warranted in view of the
limited number of children (total of 522 children) studied in
theseﬁveRCTs.Furthermore,childrenwithhigh-gradeVUR
have generally been excluded from these studies, and these
ﬁndings cannot therefore be generalized. Finally, one of the
RCTs indicates that boys with grade III VUR beneﬁt from
antibiotic prophylaxis, and there is a possibility that other
subsets of patients, who will beneﬁt from prophylaxis, will
be identiﬁed in the future.
REFERENCES
[1] M. A. Sargent, “What is the normal prevalence of vesi-
coureteral reﬂux?” Pediatric Radiology, vol. 30, no. 9, pp. 587–
593, 2000.
[2] W. C. Faust and H. G. Pohl, “Role of prophylaxis in
vesicoureteral reﬂux,” Current Opinion in Urology, vol. 17, no.
4, pp. 252–256, 2007.
[3] M. Wennerstr¨ o m ,S .H a n s s o n ,U .J o d a l ,R .S i x t ,a n dE .
Stokland, “Renal function 16 to 26 years after the ﬁrst
urinary tract infection in childhood,” Archives of Pediatrics &
Adolescent Medicine, vol. 154, no. 4, pp. 339–345, 2000.
[4] M. Wennerstr¨ om, S. Hansson, T. Hedner, A. Himmelmann,
and U. Jodal, “Ambulatory blood presssure 16–26 years after
the ﬁrst urinary tract infection in childhood,” Journal of
Hypertension, vol. 18, no. 4, pp. 485–491, 2000.
[5] J. M. P. Silva, J. S. Santos Diniz, V. S. P. Marino, et al.,
“Clinical course of 735 children and adolescents with primary
vesicoureteral reﬂux,” Pediatric Nephrology,v o l .2 1 ,n o .7 ,p p .
981–988, 2006.
[6] P. C. Gargollo and D. A. Diamond, “Therapy insight: what
nephrologists need to know about primary vesicoureteral
reﬂux,” Nature Clinical Practice Nephrology, vol. 3, no. 10, pp.
551–563, 2007.
[7] H. Nakai, H. Kakizaki, R. Konda, et al., “Clinical character-
istics of primary vesicoureteral reﬂux in infants: multicenter
retrospective study in Japan,” The Journal of Urology, vol. 169,
no. 1, pp. 309–312, 2003.
[8] V. Phan, J. Traubici, B. Hershenﬁeld, D. Stephens, N. D.
Rosenblum, and D. F. Geary, “Vesicoureteral reﬂux in infants
with isolated antenatal hydronephrosis,” Pediatric Nephrology,
vol. 18, no. 12, pp. 1224–1228, 2003.
[9] J. G. Hollowell, “Screening siblings for vesicoureteral reﬂux,”
The Journal of Urology, vol. 168, no. 5, pp. 2138–2141, 2002.
[10] S. A. Koﬀ, T. T. Wagner, and V. R. Jayanthi, “The relationship
among dysfunctional elimination syndromes, primary vesi-
coureteral reﬂux and urinary tract infections in children,” The
Journal of Urology, vol. 160, no. 3, part 2, pp. 1019–1022, 1998.
[11] American Academy of Pediatrics, Committee on Quality
Improvement, Subcommittee on Urinary Tract Infection,
“Practice parameter: the diagnosis, treatment, and evaluation
of the initial urinary tract infection in febrile infants and
young children,” Pediatrics, vol. 103, no. 4, pp. 843–852, 1999.
[12] National Institute for Health and Clinical Excellence, “Uri-
nary tract infection in children,” NICE, London, UK, 2007,
http://guidance.nice.org.uk/CG054.
[13] R. Mori,M. Lakhanpaul, and K. Verrier-Jones,“Diagnosis and
management of urinary tract infection in children: summary
of NICE guidance,” British Medical Journal, vol. 335, no. 7616,
pp. 395–397, 2007.
[14] C. W. Schwab Jr., H.-Y. Wu, H. Selman, G. H. H. Smith, H.
M. Snyder III, and D. A. Canning, “Spontaneous resolution
of vesicoureteral reﬂux: a 15-year perspective,” The Journal of
Urology, vol. 168, no. 6, pp. 2594–2599, 2002.
[15] C. S. Cooper, B. I. Chung, A. J. Kirsch, D. A. Canning, and
H. M. Snyder III, “The outcome of stopping prophylactic
antibiotics in older children with vesicoureteral reﬂux,” The
Journal of Urology, vol. 163, no. 1, pp. 269–273, 2000.
[16] R. H. Thompson, J. J. Chen, J. Pugach, S. Naseer, and
G. F. Steinhardt, “Cessation of prophylactic antibiotics for
managing persistent vesicoureteral reﬂux,” The Journal of
Urology, vol. 166, no. 4, pp. 1465–1469, 2001.Michiel Costers et al. 5
[17] S. Hellerstein and E. Nickell, “Prophylactic antibiotics in chil-
dren at risk for urinary tract infection,” Pediatric Nephrology,
vol. 17, no. 7, pp. 506–510, 2002.
[18] A. J. Al-Sayyad, J. G. Pike, and M. P. Leonard, “Can pro-
phylactic antibiotics safely be discontinued in children with
vesicoureteral reﬂux?” The Journal of Urology, vol. 174, no. 4,
part 2, pp. 1587–1589, 2005.
[19] H. Georgaki-Angelaki, S. Kostaridou, G. L. Daikos, et al.,
“Long-term follow-up of children with vesicoureteral reﬂux
with and without antibiotic prophylaxis,” Scandinavian Jour-
n a lo fI n fe cti o u sDi se a se s ,vol. 37, no. 11-12, pp. 842–845, 2005.
[20] P. P. Reddy, M. T. Evans, P. A. Hughes, et al., “Antimicrobial
prophylaxis in children with vesicoureteral reﬂux: a random-
ized prospective study of continuous therapy vs intermittent
therapy vs surveillance,” Pediatrics, vol. 100, supplement, pp.
555–556, 1997.
[21] J. Craig, L. Roy, P. Sureshkumar, J. Burke, and H. Powell,
“Long-term antibiotics to prevent urinary tract infection
in children with isolated vesicoureteric reﬂux: a placebo-
controlled randomized trial,” Journal of the American Society
of Nephrology, vol. 13, no. 3, 2002.
[22] E. H. Garin, F. Olavarria, V. G. Nieto, B. Valenciano, A.
Campos, and L. Young, “Clinical signiﬁcance of primary
vesicoureteral reﬂux and urinary antibiotic prophylaxis after
acute pyelonephritis: a multicenter, randomized, controlled
study,” Pediatrics, vol. 117, no. 3, pp. 626–632, 2006.
[ 2 3 ]P .H .C o n w a y ,A .C n a a n ,T .Z a o u t i s ,B .V .H e n r y ,R .W .
Grundmeier,andR.Keren,“Recurrenturinarytractinfections
in children: risk factors and association with prophylactic
antimicrobials,” Journal of the American Medical Association,
vol. 298, no. 2, pp. 179–186, 2007.
[24] G. Roussey-Kesler, V. Gadjos, N. Idres, et al., “Antibiotic
prophylaxis for the prevention of recurrent urinary tract
infection in children with low grade vesicoureteral reﬂux:
results from a prospective randomized study,” The Journal of
Urology, vol. 179, no. 2, pp. 674–679, 2008.
[25] M. Pennesi, L. Travan, L. Peratoner, et al., “Is antibiotic
prophylaxis in children with vesicoureteral reﬂux eﬀective
in preventing pyelonephritis and renal scars? A randomized,
controlled trial,” Pediatrics, vol. 121, no. 6, pp. e1489–e1494,
2008.
[26] E. M. Hodson, D. M. Wheeler, D. Vimalchandra, G. H. Smith,
and J. C. Craig, “Interventions for primary vesicoureteric
reﬂux,” Cochrane Database of Systematic Reviews,n o .3 ,a r t i c l e
CD001532, 2007.
[ 2 7 ]G .J .W i l l i a m s ,L .W e i ,A .L e e ,a n dJ .C .C r a i g ,“ L o n g - t e r m
antibiotics for preventing recurrent urinary tract infection
in children,” Cochrane Database of Systematic Reviews,n o .2 ,
article CD001534, 2006.
[28] J. S. Elder, C. A. Peters, B. S. Arant Jr., et al., “Paediatric
vesicoureteral reﬂux guidelines panel summary report on the
managementofprimaryvesicoureteralreﬂuxinchildren,”The
Journal of Urology, vol. 157, no. 5, pp. 1846–1851, 1997.
[29] G. Williams, A. Lee, and J. Craig, “Antibiotics for the
prevention of urinary tract infection in children: a systematic
review of randomized controlled trials,” Journal of Pediatrics,
vol. 138, no. 6, pp. 868–874, 2001.
[30] E. R. Wald, “Vesicoureteral reﬂux: the role of antibiotic
prophylaxis,” Pediatrics, vol. 117, no. 3, pp. 919–922, 2006.
[31] S. A. Lutter, M. L. Currie, L. B. Mitz, and L. A. Greenbaum,
“Antibiotic resistance patterns in children hospitalized for
urinary tract infections,” Archives of Pediatrics & Adolescent
Medicine, vol. 159, no. 10, pp. 924–928, 2005.
[32] J. M. Smellie, G. Katz, and R. N. Gruneberg, “Controlled
trial of prophylactic treatment in childhood urinary-tract
infection,” The Lancet, vol. 2, no. 8082, pp. 175–178, 1978.
[ 3 3 ]J .A .L o h r ,D .H .N u n l e y ,S .S .H o w a r d s ,a n dR .F .F o r d ,
“Prevention of recurrent urinary tract infections in girls,”
Pediatrics, vol. 59, no. 4, pp. 562–565, 1977.